Research programme: single-stranded oligonucleotide based therapeutics - Gentium

Drug Profile

Research programme: single-stranded oligonucleotide based therapeutics - Gentium

Alternative Names: Nmers; Oligotide

Latest Information Update: 28 Feb 2014

Price : $50

At a glance

  • Originator Crinos Biological Research Laboratories
  • Developer Gentium
  • Class Oligonucleotides
  • Mechanism of Action Cell membrane modulators; Heparanase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic nephropathies
  • Discontinued Chemotherapy-induced damage; Myocardial ischaemia

Most Recent Events

  • 21 Feb 2014 Gentium has been acquired by Jazz Pharmaceuticals plc
  • 28 Oct 2010 Preclinical development is ongoing Italy
  • 31 Jan 2008 Preclinical trials in Kidney disorders in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top